Inside information announcement topline results of the month 36 primary analysis of the global multi-centre phase iii clinical trial of OT-101 (0.01% atropine sulfate eye drops)
Filed with HKEX · Stock code 1477 ·
6ix is reading this filing.
View original source (HKEXnews)Ocumension Therapeutics on 6ix
Earlier from Ocumension Therapeutics
- Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2026
- 2026 Interim Report
- OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship
- OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
- Ocumension Therapeutics Announces 2023 Interim Results
Follow Ocumension Therapeutics into a list and get an email when it puts out news.
Follow Ocumension Therapeutics